Promising new drug to treat ‘deadliest’ skin cancer developed
Monday 20 November, 2017

Promising new drug to treat ‘deadliest’ skin cancer developed

Published On: Fri, Aug 19th, 2011 | Skin cancer | By BioNews

Researchers have developed a new drug to treat malignant melanoma, a deadliest form of skin cancer.

Powerful X-ray technology developed at the U.S. Department of Energy”s (DOE”s) national laboratories has revealed new insights into diseases ranging from Alzheimer”s to the swine flu, and, most recently, enabled the discovery of a groundbreaking new drug treatment for malignant melanoma.

The drug, Zelboraf (vemurafenib), has recently received Food and Drug Administration (FDA) approval. In showing the structures of diseased and disease-causing molecules at their basic level, these extremely bright light sources enable scientists to suggest potential new treatments.

“This technology is a wonderful example of how innovations at our national laboratories lead to discoveries in a wide variety of fields,” said Energy Secretary Steven Chu.

“In this case, we are pleased to have been involved in research that has shown great promise in the battle against life-threatening melanoma,” he added.

The researchers used a technique called “macromolecular X-ray crystallography” to develop a drug that would prevent the enzyme from doing this. The newly FDA-approved drug, Zelboraf (vemurafenib), was extremely successful during clinical trials in disrupting the disease and extending the lives of those diagnosed with it.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

More from Skin cancer
  • Tanning beds linked to commonest form of skin cancer
  • Sunburn `may clean up cells with genetic damage before becoming cancer`
  • Molecule in immune system `may help fight skin cancer`
  • Antibodies from rabbits reduce leukemia-associated risks
  • ‘Trial’ drug associated with 70pc response rate in chronic lymphocytic leukaemia